Skip to main content
Caplight Logo









Cantai Therapeutics

Cantai Therapeutics

Private
Philadelphia, PennsylvaniaHealthcare & Life Scienceshttps://cantaitx.com/

Last Round

Seed

Nov 20, 2023

Company Overview

Cantai Therapeutics is a biotechnology company that develops cytokine-targeting bispecific antibodies for the treatment of autoimmune and inflammatory disorders.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Application

Keywords

bispecific antibodiesvirtual biotechdrug discoveryautoimmune therapyantibody engineeringprotein engineeringAI drug discoveryin silico designbiotech startuptherapeutic pipelinepreclinical researchcomputational biologypharma R&Dbiotech platform

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Cantai Therapeutics Comparables

Compare Cantai Therapeutics with similar companies based on industry and business-model similarity.

Cantai Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Dualitas Therapeutics
86%
Navigator Medicines
86%
Ypsilon Therapeutics
79%

Cantai Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
SeedNov 20, 2023

Key People

Founding team and executive leadership

Ross Leimberg

COO and interim CEO

Executive Team

Cantai Therapeutics Investors

Notable investors and investment history

Cantai Therapeutics investors
InvestorRounds
Agent CapitalSeed
Tellus BioVenturesSeed
82VSSeed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Nov 20, 2023

    Led by 82VS and Agent Capital.

Cantai Therapeutics Filings

Explore SEC and related filing metadata, where available.

Cantai Therapeutics filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Cantai Therapeutics's valuation, stock price, and market status.

Is Cantai Therapeutics a public or private company?

Cantai Therapeutics is a private company.

What is the current stock price of Cantai Therapeutics?

Cantai Therapeutics is a private company with no public stock price. No recent secondary market data is available.

How much is Cantai Therapeutics worth (valuation)?

Valuation information for Cantai Therapeutics is not publicly available.

Can I buy Cantai Therapeutics stock?

Cantai Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Cantai Therapeutics's last funding round?

Cantai Therapeutics's most recent funding round was Seed on November 20, 2023.

Who are the main investors in Cantai Therapeutics?

Key investors in Cantai Therapeutics include Agent Capital, 82VS.

Will Cantai Therapeutics IPO soon?

No public IPO plans have been announced for Cantai Therapeutics.

How can I track Cantai Therapeutics secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Cantai Therapeutics's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersPhiladelphia, Pennsylvania
Employee Range4
Year Founded2023
Last FundingNov 20, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?